Cargando…
PCSK9 as an Atherothrombotic Risk Factor
Disturbances in lipid metabolism are among the most important risk factors for atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein in lipid metabolism that is also involved in the production of inflammatory cytokines, endothelial dysfunction...
Autores principales: | Sotler, Tadeja, Šebeštjen, Miran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916735/ https://www.ncbi.nlm.nih.gov/pubmed/36768292 http://dx.doi.org/10.3390/ijms24031966 |
Ejemplares similares
-
Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022) -
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023) -
Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
por: Petersen-Uribe, Álvaro, et al.
Publicado: (2021) -
Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
por: Hrovat, Katja, et al.
Publicado: (2022) -
The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels
por: Levstek, Tina, et al.
Publicado: (2022)